274 related articles for article (PubMed ID: 18095779)
1. An integrated approach: bisphosphonate management for the treatment of osteoporosis.
Owens G; Jackson R; Lewiecki EM
Am J Manag Care; 2007 Dec; 13 Suppl 11():S290-308; quiz S309-12. PubMed ID: 18095779
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
[TBL] [Abstract][Full Text] [Related]
3. Impact of treatment efficacy and dosing frequency on cost-effectiveness of bisphosphonate treatment for osteoporosis: a perspective.
Boonen S
Curr Med Res Opin; 2009 Oct; 25(10):2335-41. PubMed ID: 19650755
[TBL] [Abstract][Full Text] [Related]
4. [New development in bisphosphonate treatment. Clinical significance of combinatorial therapies with bisphosphonates and parathyroid hormone for osteoporosis].
Takeuchi Y
Clin Calcium; 2009 Jan; 19(1):85-90. PubMed ID: 19122268
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of an RCT to establish whether 5 or 10 years of bisphosphonate treatment is the better duration for women with a prior fracture.
Stevenson MD; Oakley JE; Lloyd Jones M; Brennan A; Compston JE; McCloskey EV; Selby PL
Med Decis Making; 2009; 29(6):678-89. PubMed ID: 19509121
[TBL] [Abstract][Full Text] [Related]
6. Is treatment of early postmenopausal women with bisphosphonates justified?
Epstein S
Int J Clin Pract; 2007 Jun; 61(6):963-71. PubMed ID: 17504359
[TBL] [Abstract][Full Text] [Related]
7. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
McHorney CA; Schousboe JT; Cline RR; Weiss TW
Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
[TBL] [Abstract][Full Text] [Related]
8. Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates.
Danese MD; Badamgarav E; Bauer DC
J Bone Miner Res; 2009 Nov; 24(11):1819-26. PubMed ID: 19419313
[TBL] [Abstract][Full Text] [Related]
9. Underdiagnosis and under-treatment of osteoporosis following fragility fracture.
Aboyoussef M; Vierkoetter KR
Hawaii Med J; 2007 Jul; 66(7):185-7. PubMed ID: 17879856
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.
Makras P; Hamdy NA; Zwinderman AH; Ballieux BE; Papapoulos SE
Bone; 2009 May; 44(5):766-71. PubMed ID: 19442613
[TBL] [Abstract][Full Text] [Related]
11. Drug insight: the use of bisphosphonates for the prevention and treatment of osteoporosis in men.
Brown SA; Guise TA
Nat Clin Pract Urol; 2007 Jun; 4(6):310-20. PubMed ID: 17551535
[TBL] [Abstract][Full Text] [Related]
12. Glucocorticoid-induced osteoporosis.
Berris KK; Repp AL; Kleerekoper M
Curr Opin Endocrinol Diabetes Obes; 2007 Dec; 14(6):446-50. PubMed ID: 17982350
[TBL] [Abstract][Full Text] [Related]
13. Refracture following fracture liaison service assessment illustrates the requirement for integrated falls and fracture services.
Langridge CR; McQuillian C; Watson WS; Walker B; Mitchell L; Gallacher SJ
Calcif Tissue Int; 2007 Aug; 81(2):85-91. PubMed ID: 17629737
[TBL] [Abstract][Full Text] [Related]
14. [Prophylaxis of glucocorticoid-induced osteoporosis].
Tanaka Y
Clin Calcium; 2006 Nov; 16(11):1858-65. PubMed ID: 17079853
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of osteoporosis in octogenarians].
Pepersack T
Rev Med Brux; 2008 Sep; 29(4):311-6. PubMed ID: 18949982
[TBL] [Abstract][Full Text] [Related]
16. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance.
Boonen S; Vanderschueren D; Venken K; Milisen K; Delforge M; Haentjens P
J Intern Med; 2008 Oct; 264(4):315-32. PubMed ID: 18823505
[TBL] [Abstract][Full Text] [Related]
17. [Absolute risk for fracture and WHO guideline. Fall and fracture in elderly people : risk factors and strategies for prevention].
Sugioka Y; Koike T;
Clin Calcium; 2007 Jul; 17(7):1059-65. PubMed ID: 17607073
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonate therapy for osteoporosis: combining optimal fracture risk reduction with patient preference.
Beard MK
Curr Med Res Opin; 2012 Jan; 28(1):141-7. PubMed ID: 22103779
[TBL] [Abstract][Full Text] [Related]
19. [Treatment with bisphosphonates: daily or once-weekly oral administration and intravenous injection].
Kitahama S; Ishii T; Wada S
Clin Calcium; 2005 Apr; 15(4):649-54. PubMed ID: 15802779
[TBL] [Abstract][Full Text] [Related]
20. Recent developments in bisphosphonate therapy.
Silverman SL; Maricic M
Semin Arthritis Rheum; 2007 Aug; 37(1):1-12. PubMed ID: 17303219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]